CoChat

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index; 8 of the 112 sources its claims cite were checked for support.

Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review

Open access
Yenet, Aderaw, Nibret, Getinet, Tegegne, Bantayehu Addis · 2023 · ClinicoEconomics and Outcomes Research

Abstract

Introduction: The availability and affordability of safe, effective, accessible, and high-quality essential medicines is a critical benchmark for achieving the right to good health, and it is also one of the goals of the global health development agenda. To that end, it is critical to conduct rigorous studies to identify the major challenges confronting developing countries, particularly those in Africa. Objective: The purpose of this review was to identify the major challenges that Africans face in obtaining reasonably priced and readily available essential medicines. Methods: Generally the Boolean operators "AND" and "OR" were employed. Making progress also involves using duplicate checks, field definitions, and comparisons of articles and criteria. The analysis included all English-language papers published in any African country between 2005 and 2022, depending on the year of publication. The technique searches electronic databases for key phrases related to essential medication availability and affordability, such as PubMed, Web of Science, Scopus, Science Direct, Plos Medicine, and Google Scholar. Results: A total of 91 articles; by using search engines and handpicking including duplicates, were primarily searched. The electronic database search earned 78 articles while only eleven studies met the criteria for review and were reviewed of which 5 (50%) were from East African countries. Inadequate human resources, financial constraints, high cost of available medications on the market, poor inventory management, manual consumption forecasting, inefficiencies in drug registration, and trade-related aspects of intellectual property rights agreement regulations are all obstacles to the availability of essential medicines in African nations. Conclusion: This review revealed that in Africa, the availability and affordability of essential medicines face numerous challenges. The primary challenge, according to the review research, is a lack of adequate financing to pay for an appropriate set of essential medications, which account for a significant portion of household spending.

Overview

CoChat Summary

TL;DR

This scoping review synthesizes 11 studies on barriers to essential medicine availability and affordability in African countries, identifying financing, pricing, supply-chain, human-resource, regulatory, and governance challenges. It concludes that availability remains below the WHO 80% benchmark and that medicines are often unaffordable, especially for poor households.

Key findings

  • The review included 11 studies: 5 qualitative, 4 cross-sectional, and 2 mixed; 5 (50%) were from East African countries. Reported barriers included inadequate human resources, financial constraints, high market prices, poor inventory management, manual consumption forecasting, inefficient drug registration, and TRIPS-related regulations.
  • Availability was low: in one 8-country survey of 3,353 hospitals and primary care facilities, mean availability of 12 essential medicines ranged from 22% to 40%; in Uganda, average availability of tracer drugs in public pharmacies was 63.3%; in South Africa, public-sector median availability of lowest-price brands and generics was 10% and 75%, while private-sector median availability was 28.6%.
  • Affordability was poor: high-cost essential medicines required the lowest-paid government employee to work 15 days for a one-month supply; branded medicines were 13.8 times more expensive than generics, and generics and brands were purchased at 2.9 and 32.6 times international reference prices, respectively. In Ethiopia, 45.6% of non-buyers cited unavailability, 45.7% cited expense, 8.7% cited ineffectiveness, and 11.8% forwent treatment due to cost.
  • The review reports that African-region median availability of essential medicines was 61.5% versus 27.3% for nonessential medicines; public-sector median availability was 40% and private-sector 78.1%, compared with 6.6% and 57.1% for nonessential medicines. The conclusion states availability does not exceed 65% and purchasing costs are unaffordable.

Methods

  • Scoping review searching PubMed, Web of Science, Scopus, Science Direct, Plos Medicine, and Google Scholar, using Boolean operators “AND” and “OR,” field specifications, duplicate checks, and article/criteria comparisons.
  • Inclusion covered English-language, open-access PDF articles on challenges to essential medicine availability, affordability, and accessibility in African countries; the abstract and inclusion criteria state 2005–2022, while the search strategy states 2005–2023. Dissertations, abstracts, editorials, clinical views, non-African studies, and abstract-only publications were excluded.
  • Methodological quality was assessed with PRISMA and an EBL critical appraisal tool; three reviewers independently assessed full texts, with 85.7% inter-observer agreement. Validity thresholds were <75% low quality, 75–90% moderate, and >90% high; most included studies were medium reliability, with 2 (20%) rated excellent.

Limitations

  • Stated by the paper: the review does not examine one influencing factor in detail or all influencing factors, but analyzes factors frequently mentioned in the reviewed articles; it also does not assess challenges across the continent as a whole and ignores national economies, policies, and regulations affecting availability and affordability.
  • Evident from the text: the search and inclusion numbers are inconsistent—the abstract reports 91 articles primarily searched and 78 from electronic databases, while the Results section reports 88 studies initially retrieved and 11 reviewed—and the date range is reported as both 2005–2022 and 2005–2023.
  • Evident from the text: only 11 studies were included, most were hospital-based, 5 (50%) were from East African countries, and most were rated medium reliability, limiting continent-wide generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2147/ceor.s413546

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 A diagram of literature searching using the PRISMA checklist.
Figure 1 A diagram of literature searching using the PRISMA checklist.CC BY-NC · PubMed Central
Figure 2 A conceptual framework of factors affecting essential medicine availability.
Figure 2 A conceptual framework of factors affecting essential medicine availability.CC BY-NC · PubMed Central

Verification

Claims the paper makes

7 Valid · 4 Not valid · 80 Not checked · 32 Own results and interpretations

56 more claims

Create a free account to see all 123 claims and to verify the 104 references still open.

See all claims — free account
  • It may state two separate claims as one. 39
  • Probably not a substantial claim. 38

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Research works printed but not linked: 16

  1. World Health Organization. WHO Guideline on Country Pharmaceutical Pricing Policies WHO Guideline on Country Pharmaceutical Pricing Policies. World Health Organization; 2020:1–70.
  2. Bruno, 2015, J Pharm Care Heal Syst, 1, 10.4172/jpchs.s2-006 · doi:10.4172/jpchs.s2-006
  3. Latifah, 2019, Rev Artic, 10, 67
  4. Fredrick, 2016, IOSR J Business Manag, 18, 63, 10.9790/487x-1810066375 · doi:10.9790/487x-1810066375
  5. Obuaku, 2014, Afr Soc Rev, 18, 42
  6. Zuma, 2019, World J Pharm Res, 8, 1532, 10.20959/wjpr20199-15303 · doi:10.20959/wjpr20199-15303
  7. Abiye, 2013, J Appl Pharma Sci, 3, 101, 10.7324/japs.2013.31017 · doi:10.7324/japs.2013.31017
  8. Irene, 2016, J Health Med Nurs, 27, 45
  9. Mendis, 2007, Lancet, 85, 279, 10.2471/blt · doi:10.2471/blt
  10. World Health Organization. Measuring affordability and price availability, components. In: Medicine Prices, Measuring Affordability and Price Availability, Components. World Health Organization; 2008:1–310.
  11. Machemedze MMR, Munyuki E. Literature review on bottlenecks to essential medicines production and procurement in East and Southern Africa; 2013:1–23.
  12. Modisakeng, 2020, MBC Heal Serv Res, 1, 1
  13. Osei-Assibey, 2017, J Biomed Pharm Res, 6, 100
  14. 2019, Ensuring Access to Medicines in East Africa: Lessons from India
  15. Baker, 2009, Am Med Assoc J Ethics, 2009, 527
  16. Mohammadshahi, 2019, Shiraz E Medical J, 20, 1, 10.5812/semj.87079.review · doi:10.5812/semj.87079.review

Cited by

See all 220

Metadata

Authors
Yenet, A., Nibret, G., & Tegegne, B. A.
Affiliations
Debre Markos University (ET)
Corresponding author
  • Yenet, Aderaw
  • Nibret, Getinet
  • Tegegne, Bantayehu Addis
Venue
ClinicoEconomics and Outcomes Research
Published
2023-06
Volume
Volume 15
Pages
443-458
ISSN
1178-6981 (ISSN-L)
OpenAlex
W4380630724
Cited by
202
References
22
Citations by year
2026: 83 · 2025: 73 · 2024: 43 · 2023: 3
FWCI
12.72
Type
journal article
Language
en
Open access
Locations
  • ClinicoEconomics and Outcomes Research (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Systems and Reforms
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
Keywords
essential medicines, drug availability, drug affordability, Africa, health care financing, drug pricing, inventory management, drug registration, intellectual property, health workforce shortage, household health expenditure, right to health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.